Additional written submissions to the Commission, including requests pursuant to section 201.12 of the Commission’s rules, shall not be accepted unless good cause is shown for accepting such submissions, or unless the submission is pursuant to a specific request by a Commissioner or Commission staff.

In accordance with sections 201.16(c) and 207.3 of the Commission’s rules, each document filed by a party to the investigations must be served on all other parties to the investigations (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.21 of the Commission’s rules.

By order of the Commission.


Lisa R. Barton, Acting Secretary to the Commission.

[FR Doc. 2012–20372 Filed 8–17–12; 8:45 am]
BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; SA INTL GMBH C/O., Sigma Aldrich Co., LLC

Correction
In notice document 2012–19191 appearing on pages 47106–47108 in the issue of Tuesday, August 7, 2012, make the following corrections:

1. On page 47106, in the third column, the document heading should appear as set forth above.
2. On page 47108, in the fifth column, in the second paragraph, in the first line of text, “September 6, 2012” should read “September 19, 2012”.

[FR Doc. C1–2012–19197 Filed 8–17–12; 8:45 am]
BILLING CODE 1505–01–D

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; Lipomed

Correction
In notice document 2012–19196 appearing on page 47108 in the issue of Tuesday, August 7, 2012, make the following corrections:

1. On page 47108, in the first column, the document heading should appear as set forth above.
2. On page 47108, in the second column, in the second full paragraph, in the eighth line of text, “September 6, 2012” should read “September 19, 2012”.

[FR Doc. C1–2012–19196 Filed 8–17–12; 8:45 am]
BILLING CODE 1505–01–D

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; Cerilliant Corporation

Correction
In notice document 2012–19199 appearing on pages 47108–47109 in the issue of Tuesday, August 7, 2012, make the following corrections:

1. On page 47108, in the third column, the document heading should appear as set forth above.
2. On page 47109, in the sixth paragraph following the table, in the eighth line of text, “September 6, 2012” should read “September 19, 2012”.

[FR Doc. C1–2012–19199 Filed 8–17–12; 8:45 am]
BILLING CODE 1505–01–D

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration; Almac Clinical Services, Inc.

By Notice dated April 17, 2012, and published in the Federal Register on April 26, 2012, 77 FR 24985, Almac Clinical Services, Inc., (ACSI), 25 Fretz Road, Souderton, Pennsylvania 18964, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxycodeone (9143)</td>
<td>II</td>
</tr>
<tr>
<td>Hydrocodeone (9150)</td>
<td>II</td>
</tr>
<tr>
<td>Tapentadol (9780)</td>
<td>II</td>
</tr>
<tr>
<td>Fentanyl (9801)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to import small quantities of the listed controlled substances in dosage form to conduct clinical trials.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Almac Clinical Services, Inc. (ACSI) to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international conventions, or protocols in effect on May 1, 1971. DEA has investigated Almac Clinical Services, Inc. (ACSI) to ensure that the company’s registration is consistent with the public interest.

The investigation has included inspection and testing of the company’s